Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322073 | 1.00 | RIPK1 (0.52) | RIPK1ROCK2USP30NR1H2NR1H3 | |
| SCHEMBL8214939 | 0.88 | ROCK2 (0.53) | RIPK1ROCK2USP30NR1H2NR1H3 | |
| SCHEMBL321027 | 0.88 | ROCK2 (0.53) | RIPK1ROCK2USP30NR1H2NR1H3 | |
| SCHEMBL28089302 | 0.86 | PARP14 (0.53) | RIPK1NR1H2NR1H3UCHL1ALDH1A1 | |
| SCHEMBL6960066 | 0.86 | RIPK1 (0.69) | RIPK1NR1H2NR1H3NPC1LMNA | |
| SCHEMBL18642714 | 0.86 | RIPK1 (0.69) | RIPK1NR1H2NR1H3NPC1LMNA | |
| SCHEMBL878861 | 0.85 | NPSR1 (0.56) | RIPK1ROCK2NR1H2NR1H3UCHL1 | |
| SCHEMBL1655270 | 0.85 | RIPK1 (0.53) | RIPK1NR1H2NR1H3UCHL1NPSR1 | |
| SCHEMBL17538788 | 0.84 | ROCK2 (0.55) | RIPK1ROCK2USP30UCHL1NPSR1 | |
| SCHEMBL14494457 | 0.84 | RIPK1 (0.47) | RIPK1ROCK2UCHL1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3183248-B1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-11 | — | — | EP | disclosed |
| CN-107108581-B | Tieback benzamide derivatives as potent ROCK inhibitors | 百时美施贵宝公司 | 2020-06-23 | — | — | CN | disclosed |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10391089-B2 | PRMT5 inhibitors and uses therof | Epizyme, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| WO-2012006202-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006202-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| EP-2331499-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM6 | RIPK1 3006/4885ROCK2 3475/4885USP30 4206/4885 |
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | RIPK1 930/4885ROCK2 781/4885USP30 1574/4885 |
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | RIPK1 2604/4885ROCK2 966/4885USP30 3587/4885 |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | RIPK1 471/4885ROCK2 989/4885USP30 1639/4885 |
| US-10391089-B2 | PRMT5 inhibitors and uses therof | PRMT5, PRMT1, PRMT6 | RIPK1 940/4885ROCK2 1459/4885USP30 1487/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | RIPK1 4605/4885ROCK2 3068/4885USP30 2330/4885 |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT6 | RIPK1 930/4885ROCK2 781/4885USP30 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.